Semigran Marc
Known title: Chief Development OfficerCIK: 0001691494
Associated companies
Transaction History
| EWTX | ▲ Buy | Option Exercise | 29,709 | $266K | 12/24/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 27,980 | $830K | 12/24/2024 | View on chart |
| EWTX | ▼ Sell | Open Market | 1,729 | $52K | 12/24/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Edgewise Therapeutics Doses First Patient in Phase 2 Trial
Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.
Edgewise Therapeutics Doses First Patient in Phase 2 Trial. Edgewise Therapeutics has dosed the first participant in its Phase 2 EQUINOX-HFpEF trial for EDG-15400, a drug intended to treat heart failure with preserved ejection fraction. This marks a key clinical milestone for the company. The stock is currently trading near its 52-week high, with analysts maintaining an average price target of $52.62.